The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Eptacog Alfa (rFVIIa) Market Research Report 2025
Synopsis
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
The global Eptacog Alfa (rFVIIa) market was valued at US$ 1190 million in 2023 and is anticipated to reach US$ 1654.2 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa).
Report Scope
The Eptacog Alfa (rFVIIa) market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eptacog Alfa (rFVIIa) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eptacog Alfa (rFVIIa) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
The global Eptacog Alfa (rFVIIa) market was valued at US$ 1190 million in 2023 and is anticipated to reach US$ 1654.2 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa).
Report Scope
The Eptacog Alfa (rFVIIa) market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eptacog Alfa (rFVIIa) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eptacog Alfa (rFVIIa) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Eptacog Alfa (rFVIIa) Market Overview
1.1 Product Overview and Scope of Eptacog Alfa (rFVIIa)
1.2 Eptacog Alfa (rFVIIa) Segment by Type
1.2.1 Global Eptacog Alfa (rFVIIa) Market Value Comparison by Type (2024-2030)
1.2.2 Freeze-dried Preparation
1.2.3 Freeze-dried Powder
1.3 Eptacog Alfa (rFVIIa) Segment by Application
1.3.1 Global Eptacog Alfa (rFVIIa) Market Value by Application: (2024-2030)
1.3.2 Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Factor VII Deficiency
1.3.5 Glanzmann Thrombasthenia (GT)
1.4 Global Eptacog Alfa (rFVIIa) Market Size Estimates and Forecasts
1.4.1 Global Eptacog Alfa (rFVIIa) Revenue 2019-2030
1.4.2 Global Eptacog Alfa (rFVIIa) Sales 2019-2030
1.4.3 Global Eptacog Alfa (rFVIIa) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Eptacog Alfa (rFVIIa) Market Competition by Manufacturers
2.1 Global Eptacog Alfa (rFVIIa) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Eptacog Alfa (rFVIIa) Average Price by Manufacturers (2019-2024)
2.4 Global Eptacog Alfa (rFVIIa) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eptacog Alfa (rFVIIa), Product Type & Application
2.7 Eptacog Alfa (rFVIIa) Market Competitive Situation and Trends
2.7.1 Eptacog Alfa (rFVIIa) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eptacog Alfa (rFVIIa) Players Market Share by Revenue
2.7.3 Global Eptacog Alfa (rFVIIa) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eptacog Alfa (rFVIIa) Retrospective Market Scenario by Region
3.1 Global Eptacog Alfa (rFVIIa) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Sales by Region: 2019-2030
3.2.1 Global Eptacog Alfa (rFVIIa) Sales by Region: 2019-2024
3.2.2 Global Eptacog Alfa (rFVIIa) Sales by Region: 2025-2030
3.3 Global Eptacog Alfa (rFVIIa) Global Eptacog Alfa (rFVIIa) Revenue by Region: 2019-2030
3.3.1 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2019-2024
3.3.2 Global Eptacog Alfa (rFVIIa) Revenue by Region: 2025-2030
3.4 North America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.4.1 North America Eptacog Alfa (rFVIIa) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Eptacog Alfa (rFVIIa) Sales by Country (2019-2030)
3.4.3 North America Eptacog Alfa (rFVIIa) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.5.1 Europe Eptacog Alfa (rFVIIa) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Eptacog Alfa (rFVIIa) Sales by Country (2019-2030)
3.5.3 Europe Eptacog Alfa (rFVIIa) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.6.1 Asia Pacific Eptacog Alfa (rFVIIa) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Eptacog Alfa (rFVIIa) Sales by Country (2019-2030)
3.6.3 Asia Pacific Eptacog Alfa (rFVIIa) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.7.1 Latin America Eptacog Alfa (rFVIIa) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Eptacog Alfa (rFVIIa) Sales by Country (2019-2030)
3.7.3 Latin America Eptacog Alfa (rFVIIa) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eptacog Alfa (rFVIIa) Market Facts & Figures by Country
3.8.1 Middle East and Africa Eptacog Alfa (rFVIIa) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Eptacog Alfa (rFVIIa) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Eptacog Alfa (rFVIIa) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2019-2030)
4.1.1 Global Eptacog Alfa (rFVIIa) Sales by Type (2019-2024)
4.1.2 Global Eptacog Alfa (rFVIIa) Sales by Type (2025-2030)
4.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Type (2019-2030)
4.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2019-2030)
4.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Type (2019-2024)
4.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Type (2025-2030)
4.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Type (2019-2030)
4.3 Global Eptacog Alfa (rFVIIa) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2019-2030)
5.1.1 Global Eptacog Alfa (rFVIIa) Sales by Application (2019-2024)
5.1.2 Global Eptacog Alfa (rFVIIa) Sales by Application (2025-2030)
5.1.3 Global Eptacog Alfa (rFVIIa) Sales Market Share by Application (2019-2030)
5.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2019-2030)
5.2.1 Global Eptacog Alfa (rFVIIa) Revenue by Application (2019-2024)
5.2.2 Global Eptacog Alfa (rFVIIa) Revenue by Application (2025-2030)
5.2.3 Global Eptacog Alfa (rFVIIa) Revenue Market Share by Application (2019-2030)
5.3 Global Eptacog Alfa (rFVIIa) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 LFB SA
6.2.1 LFB SA Corporation Information
6.2.2 LFB SA Description and Business Overview
6.2.3 LFB SA Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LFB SA Eptacog Alfa (rFVIIa) Product Portfolio
6.2.5 LFB SA Recent Developments/Updates
6.3 GENERIUM
6.3.1 GENERIUM Corporation Information
6.3.2 GENERIUM Description and Business Overview
6.3.3 GENERIUM Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GENERIUM Eptacog Alfa (rFVIIa) Product Portfolio
6.3.5 GENERIUM Recent Developments/Updates
6.4 Northland-bio
6.4.1 Northland-bio Corporation Information
6.4.2 Northland-bio Description and Business Overview
6.4.3 Northland-bio Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Northland-bio Eptacog Alfa (rFVIIa) Product Portfolio
6.4.5 Northland-bio Recent Developments/Updates
6.5 CSL
6.5.1 CSL Corporation Information
6.5.2 CSL Description and Business Overview
6.5.3 CSL Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CSL Eptacog Alfa (rFVIIa) Product Portfolio
6.5.5 CSL Recent Developments/Updates
6.6 Shire (Takeda)
6.6.1 Shire (Takeda) Corporation Information
6.6.2 Shire (Takeda) Description and Business Overview
6.6.3 Shire (Takeda) Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Shire (Takeda) Eptacog Alfa (rFVIIa) Product Portfolio
6.6.5 Shire (Takeda) Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Eptacog Alfa (rFVIIa) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Eptacog Alfa (rFVIIa) Product Portfolio
6.7.5 Bayer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eptacog Alfa (rFVIIa) Industry Chain Analysis
7.2 Eptacog Alfa (rFVIIa) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eptacog Alfa (rFVIIa) Production Mode & Process
7.4 Eptacog Alfa (rFVIIa) Sales and Marketing
7.4.1 Eptacog Alfa (rFVIIa) Sales Channels
7.4.2 Eptacog Alfa (rFVIIa) Distributors
7.5 Eptacog Alfa (rFVIIa) Customers
8 Eptacog Alfa (rFVIIa) Market Dynamics
8.1 Eptacog Alfa (rFVIIa) Industry Trends
8.2 Eptacog Alfa (rFVIIa) Market Drivers
8.3 Eptacog Alfa (rFVIIa) Market Challenges
8.4 Eptacog Alfa (rFVIIa) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
